Review: Reconsidering the value of fibrates: lessons from the trials

Abstract

Therapy with both statins and fibrates reduces the risk of coronary events. In the fibrate studies the extent of reduction is disproportionately large in people with features of the metabolic syndrome such as overweight, elevated baseline levels of plasma triglyceride and low baseline high density lipoprotein-cholesterol (HDL-c). In such people, treatment with fibrates results in a 40—50% reduction in coronary heart disease events, much greater than predicted (from the human population studies) by the joint changes in concentrations of HDL-c or low density lipoprotein-cholesterol.

Keywords

fibrates statins coronary heart disease metabolic syndrome.

Get full access to this article

View all access options for this article.

References

Barter P. Gemfibrozil. Journal of Drug Evaluation: Cardiovascular Medicine 2002;1:13-39.

Todd PA , Ward A. Gemfibrozil: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia. Drugs 1998;36:314-39.

Fruchart J-C. , Staels B. , Duriez P. The role of fibric acids in atherosclerosis . Curr Athero Rep 2001;3:83-92.

Report from the Committee of Principal Investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978;40:1069-118.

Frick MH , Elo O. , Haapa K. et al. Helsinki Heart Study Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237-45.

Bloomfield Rubins H. , Robins SJ , Collins D. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-18.

The BIP Study Group. Secondary prevention by raising HDL-cholesterol and reducing triglycerides in patients with coronary artery disease. The bezafibrate infarction prevention (BIP) study. Circulation 2000;102:21-7.

Ginsberg HN , Huang LS The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis . J Cardiovasc Risk 2000;7: 325-31.

Cohn G. , Valdes G. , Capuzzi DM Pathophysiology and treatment of the dyslipidemia of insulin resistance. Curr Cardiol Rep 2001;3:416-23.

10.

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.

11.

Manninen V. , Elo O. , Frick H. et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260:641-51.

12.

Manninen V. , Tenkanen L. , Koskinen P. et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992;85:27-45.

13.

Tenkanen L. , Manttari M. , Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation 1995 ;92:1779-85.

14.

Koskinen P. , Manttari M. , Manninen V. et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992;15:820-5.

15.

Heady JA , Morris JN , Oliver MF WHO clofibrate/cholesterol trial: clarifications. Lancet 1992;340:1405-06.

16.

Robins SJ , Collins D. , Wittes JT et al. Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: A randomised controlled trial. JAMA 2001;285:1585-91.

17.

Bloomfield Rubins H. , Davenport J. , Babikian V. et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 2001;103:2828-33.

18.

Shepherd J. , Cobbe S. , Ford I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-07.

19.

West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the west of Scotland coronary prevention study (WOSCOPS). Circulation 1998;97:1440-5.

20.

Downs JR , Clearfield M. , Weis S. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998;279:1615-22.

21.

Gotto AM , Whitney E. , Stein EA et al. Relation between baseline and ontreatment lipid parameters and first acute major coronary events in the air force/Texas coronary atherosclerosis prevention study (AFCAPS/ TexCAPS). Circulation 2000;101:477-84.

22.

Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.

23.

Pedersen TR , Olsson AG , Faergeman O. et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian simvastatin survival study (4S). Circulation 1998;97:145360.

24.

Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian simvastatin survival study (4S). Lancet 1995;345:1274-5.

25.

Ballantyne CM , Olsson AG , Cook TJ et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001; 104:3046-51.

26.

The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.

27.

Simes RJ , Marschner IC , Hunt D. et al. Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial . Circulation 2002;105:1162-9.

28.

Sacks FM , Pfeffer MA , Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-09.

29.

Sacks FM , Tonkin AM , Shepherd J. et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The prospective pravastatin pooling project . Circulation 2000;102:1893-900.

30.

Heart Protection Study Collaborative Group. MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360 (9326):7-22.

31.

Frick MH , Syvanne M. , Nieminen MS et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997;96:2137-43.

32.

Ericsson CG , Hamsten A. , Nilsson J. et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849-53.

33.

Dais Investigators . Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905-10.